Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on 68Ga-DOTATATE PET/MR

被引:0
|
作者
Gao, Jing [1 ]
Zhou, Jinxin [1 ]
Liu, Chang [1 ]
Pan, Yu [1 ]
Lin, Xiaozhu [1 ]
Zhang, Yifan [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Nucl Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
Neuroendocrine tumors; PET/MR; Ga-68-DOTATATE; SSTR-RADS-3A; SSTR-RADS-3B; NONMETASTATIC LYMPH-NODES; DIFFUSION-WEIGHTED MRI; BONE; CONSENSUS; DIFFERENTIATION; FEASIBILITY; METASTASES; MANAGEMENT;
D O I
10.1007/s00432-024-05776-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Somatostatin receptor (SSTR)-targeted PET imaging has emerged as a common approach to evaluating those patients with well-differentiated neuroendocrine tumors (NETs). The SSTR reporting and data system (SSTR-RADS) version 1.0 provides a means of categorizing lesions from 1 to 5 according to the likelihood of NET involvement, with SSTR-RADS-3A (soft-tissue) and SSTR-RADS-3B (bone) lesions being those suggestive of but without definitive NET involvement. The goal of the present study was to assess the ability of Ga-68-DOTATATE PET/MR imaging data to predict outcomes for indeterminate SSTR-RADS-3A and 3B lesions. Methods NET patients with indeterminate SSTR-RADS-3A or SSTR-RADS-3B lesions who underwent Ga-68-DOTATATE PET/MR imaging from April 2020 through August 2023 were retrospectively evaluated. All patients underwent follow-up through December 2023 (median, 17 months; (3-31 months)), with imaging follow-up or biopsy findings ultimately being used to classify lesions as malignant or benign. Lesion maximum standardized uptake value (SUVmax) along with minimum and mean apparent diffusion coefficient (ADCmin and ADCmean) values were measured and assessed for correlations with outcomes on follow-up. Results In total, 33 indeterminate SSTR-RADS-3 lesions from 22 patients (19 SSTR-RADS-3A and 14 SSTR-RADS-3B) were identified based upon baseline Ga-68-DOTATATE PET/MR findings. Over the course of follow-up, 16 of these lesions (48.5%) were found to exhibit true NET positivity, including 9 SSTR-RADS-3A and 7 SSTR-RADS-3B lesions. For SSTR-RADS-3A lymph nodes, a diameter larger than 0.7 cm and an ADCmin of 779 x 10(-6)mm(2)/s or lower were identified as being more likely to be associated with metastatic lesions. Significant differences in ADCmin and ADCmean were identified when comparing metastatic and non-metastatic SSTR-RADS-3B bone lesions (P < 0.05), with these parameters offering a high predictive ability (AUC = 0.94, AUC = 0.86). Conclusion Both diameter and ADCmin can aid in the accurate identification of the nature of lesions associated with SSTR-RADS-3A lymph nodes, whereas ADCmin and ADCmean values can inform the accurate interpretation of SSTR-RADS-3B bone lesions.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Diagnositc and Prognostic Role of 68GA-DOTATATE PET in Patients with Neuroendocrine Tumors
    Marciello, F.
    Faggiano, A.
    Aloi, L.
    Caraco, C.
    Ramundo, V
    Marotta, V
    Del Prete, M.
    Carrat, A. C.
    Colao, A.
    La Storia, S.
    NEUROENDOCRINOLOGY, 2012, 96 : 46 - 46
  • [2] Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma
    Kurz, Sylvia C.
    Zan, Elcin
    Cordova, Christine
    Troxel, Andrea B.
    Barbaro, Marissa
    Silverman, Joshua S.
    Snuderl, Matija
    Zagzag, David
    Kondziolka, Douglas
    Golfinos, John G.
    Chi, Andrew S.
    Sulman, Erik P.
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 680 - 686
  • [3] Role of 68Ga-DOTATATE PET/CT in evaluation of patients with lung neuroendocrine tumors
    Kunikowska, J.
    Matyskiel, R.
    Zemczak, A.
    Pawlak, D.
    Krolicki, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S188 - S188
  • [4] A reassessment of the clinical utility of 68Ga-DOTATATE PET/CT in patients with gastroenteropancreatic neuroendocrine tumors
    Prela, Orjola
    Caveney, Brennen
    Strawderman, Myla S.
    Carpizo, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Wild, Damian
    Bomanji, Jamshed B.
    Benkert, Pascal
    Maecke, Helmut
    Ell, Peter J.
    Reubi, Jean Claude
    Caplin, Martyn E.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (03) : 364 - 372
  • [6] The Influence of 68Ga-DOTATATE PET/CT Imaging in the Management Decision of Patients with Neuroendocrine Tumors
    Skoura, E.
    AlMukhalid, O. M.
    Panagiotidis, E.
    Al Harbi, M.
    Kayani, I.
    Michopoulou, S.
    Syed, R.
    Ell, P. J.
    Caplin, M. E.
    Bomanji, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S230 - S231
  • [7] Preoperative prediction of pancreatic neuroendocrine tumor grade based on 68Ga-DOTATATE PET/CT
    Jiao Ma
    Xiaoyong Wang
    Mingsong Tang
    Chunyin Zhang
    Endocrine, 2024, 83 : 502 - 510
  • [8] Preoperative prediction of pancreatic neuroendocrine tumor grade based on 68Ga-DOTATATE PET/CT
    Ma, Jiao
    Wang, Xiaoyong
    Tang, Mingsong
    Zhang, Chunyin
    ENDOCRINE, 2024, 83 (02) : 502 - 510
  • [9] Comparison of PET/CT images with 68Ga-DOTATATE and 68Ga-DOTANOC in Patients with Intestinal Neuroendocrine Tumors: Preliminary Report
    Amaral, H.
    Pruzzo, R.
    Redondo, F.
    Gil, M.
    Bolelli, J.
    Roesch, F.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S132 - S133
  • [10] Should 68Ga-DOTATATE PET/CT be Performed Routinely in Patients with Neuroendocrine Tumors Before Surgical Resection?
    Nasim T. Babazadeh
    Devan J. Schlund
    Tyler Cornelius
    Jagadeesh S. Singh
    John F. Tierney
    Meri Chen
    Xavier M. Keutgen
    World Journal of Surgery, 2020, 44 : 604 - 611